vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and NORTECH SYSTEMS INC (NSYS). Click either name above to swap in a different company.
Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $30.3M, roughly 1.5× NORTECH SYSTEMS INC). NORTECH SYSTEMS INC runs the higher net margin — 3.0% vs -23.3%, a 26.2% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs 5.9%). Over the past eight quarters, NORTECH SYSTEMS INC's revenue compounded faster (-5.9% CAGR vs -18.3%).
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Nortech Systems Inc is a global electronics manufacturing services provider. It delivers end-to-end solutions covering product design, prototyping, full-scale production, and supply chain management for clients operating in medical technology, industrial automation, aerospace and defense, and transportation sectors. It specializes in high-reliability, regulatory-compliant electronic components and assemblies tailored to strict industry standards.
AMRN vs NSYS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $30.3M |
| Net Profit | $-10.5M | $897.0K |
| Gross Margin | — | 16.7% |
| Operating Margin | 35.5% | 3.0% |
| Net Margin | -23.3% | 3.0% |
| Revenue YoY | 7.0% | 5.9% |
| Net Profit YoY | 33.0% | 160.7% |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | $30.3M | ||
| Q3 25 | $49.7M | $30.5M | ||
| Q2 25 | $72.7M | $30.7M | ||
| Q1 25 | $42.0M | $26.9M | ||
| Q4 24 | $62.3M | $28.6M | ||
| Q3 24 | $42.3M | $31.4M | ||
| Q2 24 | $67.5M | $33.9M |
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $897.0K | ||
| Q3 25 | $-7.7M | $-146.0K | ||
| Q2 25 | $-14.1M | $313.0K | ||
| Q1 25 | $-15.7M | $-1.3M | ||
| Q4 24 | $-48.6M | $-1.5M | ||
| Q3 24 | $-25.1M | $-739.0K | ||
| Q2 24 | $1.5M | $157.0K |
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | 16.7% | ||
| Q3 25 | 44.7% | 16.5% | ||
| Q2 25 | 69.2% | 15.8% | ||
| Q1 25 | 59.8% | 11.4% | ||
| Q4 24 | -15.4% | 9.9% | ||
| Q3 24 | 38.5% | 12.2% | ||
| Q2 24 | 63.4% | 13.6% |
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 3.0% | ||
| Q3 25 | -22.4% | 3.1% | ||
| Q2 25 | -22.0% | 2.4% | ||
| Q1 25 | -39.9% | -6.0% | ||
| Q4 24 | -84.3% | -4.3% | ||
| Q3 24 | -59.5% | -1.5% | ||
| Q2 24 | -0.8% | 1.0% |
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | 3.0% | ||
| Q3 25 | -15.6% | -0.5% | ||
| Q2 25 | -19.4% | 1.0% | ||
| Q1 25 | -37.4% | -4.9% | ||
| Q4 24 | -78.0% | -5.2% | ||
| Q3 24 | -59.4% | -2.4% | ||
| Q2 24 | 2.3% | 0.5% |
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | $0.32 | ||
| Q3 25 | $-0.02 | $-0.05 | ||
| Q2 25 | $-0.03 | $0.12 | ||
| Q1 25 | $-0.04 | $-0.48 | ||
| Q4 24 | $-0.12 | $-0.51 | ||
| Q3 24 | $-0.06 | $-0.27 | ||
| Q2 24 | $0.00 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $1.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $34.5M |
| Total Assets | $645.8M | $71.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | $1.7M | ||
| Q3 25 | $286.6M | $1.3M | ||
| Q2 25 | $298.7M | $652.0K | ||
| Q1 25 | $281.8M | $1.2M | ||
| Q4 24 | $294.2M | $916.0K | ||
| Q3 24 | $305.7M | $1.2M | ||
| Q2 24 | $306.7M | $1.5M |
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | $34.5M | ||
| Q3 25 | $458.9M | $33.4M | ||
| Q2 25 | $464.9M | $33.4M | ||
| Q1 25 | $473.7M | $32.8M | ||
| Q4 24 | $486.2M | $34.0M | ||
| Q3 24 | $531.4M | $35.7M | ||
| Q2 24 | $551.9M | $36.1M |
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $71.9M | ||
| Q3 25 | $659.8M | $74.8M | ||
| Q2 25 | $670.1M | $74.8M | ||
| Q1 25 | $655.7M | $73.5M | ||
| Q4 24 | $685.3M | $72.4M | ||
| Q3 24 | $750.6M | $77.0M | ||
| Q2 24 | $799.9M | $76.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $5.6M |
| Free Cash FlowOCF − Capex | — | $5.5M |
| FCF MarginFCF / Revenue | — | 18.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | 6.25× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | $5.6M | ||
| Q3 25 | $-12.7M | $-92.0K | ||
| Q2 25 | $16.6M | $157.0K | ||
| Q1 25 | $-12.5M | $-2.9M | ||
| Q4 24 | $-13.3M | $793.0K | ||
| Q3 24 | $-2.4M | $-1.6M | ||
| Q2 24 | $-2.7M | $-4.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $5.5M | ||
| Q3 25 | — | $-242.0K | ||
| Q2 25 | — | $58.0K | ||
| Q1 25 | — | $-3.2M | ||
| Q4 24 | — | $503.0K | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | — | $-4.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 18.0% | ||
| Q3 25 | — | -0.8% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | -11.9% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | -5.2% | ||
| Q2 24 | — | -13.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.25× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.81× | -27.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
NSYS
| Medical Imaging | $11.4M | 37% |
| Medical Device | $8.0M | 26% |
| Industrial | $7.3M | 24% |
| Aerospace And Defense | $3.7M | 12% |
